tradingkey.logo

Genfit SA

GNFT
查看詳細走勢圖
4.850USD
0.000
收盤 12/26, 16:00美東報價延遲15分鐘
242.51M總市值
--本益比TTM

Genfit SA

4.850
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

0.00%

1月

0.00%

6月

+26.30%

今年開始到現在

+30.55%

1年

+30.73%

查看詳細走勢圖

TradingKey Genfit SA股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比低,近一個月多位分析師給出公司評級為強力買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Genfit SA評分

相關信息

行業排名
269 / 501
全市場排名
480 / 4682
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 7 分析師
強力買入
評級
8.683
目標均價
+79.04%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Genfit SA亮點

亮點風險
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
業績高增長
公司營業收入穩步增長,連續3年增長147.99%
業績增長期
公司處於發展階段,最新年度總收入62.29M美元
業績轉盈
公司業績轉盈,最新年度盈利美元
估值高估
公司最新PE估值145.37,處於3年歷史高位
機構減倉
最新機構持股80.73K股,環比減少89.49%

Genfit SA新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Genfit SA簡介

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
公司代碼GNFT
公司Genfit SA
CEOPrigent (Pascal)
網址https://www.genfit.fr/

常見問題

Genfit SA(GNFT)的當前股價是多少?

Genfit SA(GNFT)的當前股價是 4.850。

Genfit SA 的股票代碼是什麼?

Genfit SA的股票代碼是GNFT。

Genfit SA股票的52週最高點是多少?

Genfit SA股票的52週最高點是4.929。

Genfit SA股票的52週最低點是多少?

Genfit SA股票的52週最低點是2.550。

Genfit SA的市值是多少?

Genfit SA的市值是242.51M。

Genfit SA的淨利潤是多少?

Genfit SA的淨利潤為1.51M。

現在Genfit SA(GNFT)的股票是買入、持有還是賣出?

根據分析師評級,Genfit SA(GNFT)的總體評級為--,目標價格為8.683。

Genfit SA(GNFT)股票的每股收益(EPS TTM)是多少

Genfit SA(GNFT)股票的每股收益(EPS TTM)是0.029。
KeyAI